Fig. 1
From: Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Graphical summary of unresolved questions in first therapies for CLL. BTKi—Bruton’s tyrosine kinase inhibitor; BTKi-Ven—Bruton’s tyrosine kinase inhibitor-venetoclax combination; CIT—chemoimmunotherapy; CR—complete response; Ib-Ven ( ±) O—ibrutinib-venetoclax ± obinutuzumab; mAb—monoclonal antibody; PFS—progression-free survival; uMRD—undetectable measurable residual disease; VenO—venetoclax-obinutuzumab